Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol

Abstract

A major impediment to the successful use of Taxol in the treatment of cancer is the development of drug resistance. The major cellular target of Taxol is the microtubule that is comprised of alpha- and beta-tubulin heterodimers. Binding sites for Taxol have been delineated on the beta-tubulin subunit that has six isotypes. We have recently described increased expression of the brain-specific human class III beta-tubulin isotype, encoded by the Hbeta4 gene, in both Taxol-resistant ovarian tumours and non-small-cell lung cancer cell lines. To evaluate directly the role of the class III beta-tubulin isotype in mediating Taxol resistance, antisense phosphorothioate oligodeoxynucleotides (ODN) targeted against various regions of the Hbeta4 gene have been designed and examined for their efficacy in reducing Hbeta4 gene and protein expression. Taxol-resistant lung cancer cells, A549-T24, which are 17-fold resistant to Taxol and display a fourfold increase in Hbeta4 expression compared to the parental A549 cells, were treated with 1 microM antisense ODNs. Two ODNs, AS1 and AS3, were found to reduce mRNA expression by 40-50%, as determined by reverse transcription polymerase chain reaction. A concentration-dependent reduction in Hbeta4 mRNA expression was demonstrated with AS1 ODN. Immunofluorescence staining of cells treated with AS1 ODN revealed a decrease in class III protein expression which corresponded to a 39% increase in sensitivity to Taxol (P < 0.005). These findings support an important role for Hbeta4 (class III) beta-tubulin expression in Taxol resistance and have potential implications for the treatment of Taxol-resistant tumours.

References 23

1. 1.

   Akhtar S., Juliano R. L. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 1992;2(5):139-144.

   Not in our library10.1016/0962-8924(92)90100-2

2. 2.

   Alahari S. K., Dean N. M., Fisher M. H., Delong R., Manoharan M., Tivel K. L., Juliano R. L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996;50(4):808-819.

   Not in our library

3. 3.

   Banerjee A., Roach M. C., Trcka P., Ludueña R. F. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem. 1990;265(3):1794-1799.

   Not in our library

4. 4.

   Derry W. B., Wilson L., Khan I. A., Luduena R. F., Jordan M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997;36(12):3554-3562.

   Not in our library10.1021/bi962724m

5. 5.

   Dumontet C., Duran G. E., Steger K. A., Beketic-Oreskovic L., Sikic B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996;56(5):1091-1097.

   Not in our library

6. 6.

   Giannakakou P., Sackett D. L., Kang Y. K., Zhan Z., Buters J. T., Fojo T., Poruchynsky M. S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272(27):17118-17125.

   Not in our library10.1074/jbc.272.27.17118

7. 7.

   Gonzalez-Garay M. L., Cabral F. Overexpression of an epitope-tagged beta-tubulin in Chinese hamster ovary cells causes an increase in endogenous alpha-tubulin synthesis. Cell Motil Cytoskeleton. 1995;31(4):259-272.

   Not in our library10.1002/cm.970310403

8. 8.

   Haber M., Burkhart C. A., Regl D. L., Madafiglio J., Norris M. D., Horwitz S. B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995;270(52):31269-31275.

   Not in our library10.1074/jbc.270.52.31269

9. 9.

   Horwitz S. B., Cohen D., Rao S., Ringel I., Shen H. J., Yang C. P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55-61.

   Not in our library

10. 10.

    Hélène C., Toulmé J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990;1049(2):99-125.

    Not in our library10.1016/0167-4781(90)90031-v

11. 11.

    Jaffrézou J. P., Dumontet C., Derry W. B., Durán G., Chen G., Tsuchiya E., Wilson L., Jordan M. A., Sikic B. I. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995;7(10-11):517-527.

    Not in our library

12. 12.

    Jordan M. A., Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 1998;10(1):123-130.

    Not in our library10.1016/s0955-0674(98)80095-1

13. 13.

    Kavallaris M., Kuo D. Y., Burkhart C. A., Regl D. L., Norris M. D., Haber M., Horwitz S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100(5):1282-1293.

    Not in our library10.1172/jci119642

14. 14.

    Ludueña R. F. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998;178:207-275.

    Not in our library10.1016/s0074-7696(08)62138-5

15. 15.

    Mitchison T., Kirschner M. Dynamic instability of microtubule growth. Nature. 1984;312(5991):237-242.

    Not in our library10.1038/312237a0

16. 16.

    Panda D., Miller H. P., Banerjee A., Ludueña R. F., Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A. 1994;91(24):11358-11362.

    Not in our library10.1073/pnas.91.24.11358

17. 17.
    Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells · 1998

    No notice
18. 18.

    Ranganathan S., Dexter D. W., Benetatos C. A., Chapman A. E., Tew K. D., Hudes G. R. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996;56(11):2584-2589.

    Not in our library

19. 19.

    Ranganathan S., Dexter D. W., Benetatos C. A., Hudes G. R. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta. 1998;1395(2):237-245.

    Not in our library10.1016/s0167-4781(97)00168-1

20. 20.

    Rao S., Orr G. A., Chaudhary A. G., Kingston D. G., Horwitz S. B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem. 1995;270(35):20235-20238.

    Not in our library10.1074/jbc.270.35.20235

21. 21.

    Stewart A. J., Canitrot Y., Baracchini E., Dean N. M., Deeley R. G., Cole S. P. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol. 1996;51(4):461-469.

    Not in our library10.1016/0006-2952(95)02220-1

22. 22.

    Sullivan K. F., Cleveland D. W. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci U S A. 1986;83(12):4327-4331.

    Not in our library10.1073/pnas.83.12.4327

23. 23.

    Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372(6504):333-335.

    Not in our library10.1038/372333a0

Cited by papers we hold 3

• LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization · 2019
  Corrected
• An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance · 2017
  No notice
• Class III β-tubulin expression and in vitro resistance to microtubule targeting agents · 2009
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.